Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) closed the day trading at $80.05 down -1.26% from the previous closing price of $81.07. In other words, the price has decreased by -$1.26 from its previous closing price. On the day, 0.69 million shares were traded. MIRM stock price reached its highest trading level at $82.58 during the session, while it also had its lowest trading level at $79.4.
Ratios:
For a better understanding of MIRM, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 93.35. For the most recent quarter (mrq), Quick Ratio is recorded 3.16 and its Current Ratio is at 3.31. In the meantime, Its Debt-to-Equity ratio is 1.09 whereas as Long-Term Debt/Eq ratio is at 1.08.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 22 ’25 when Ramasastry Saira sold 5,000 shares for $80.00 per share. The transaction valued at 400,000 led to the insider holds 0 shares of the business.
GREY MICHAEL G sold 50,000 shares of MIRM for $3,900,000 on Dec 19 ’25. The Director now owns 0 shares after completing the transaction at $78.00 per share. On Dec 22 ’25, another insider, SAIRA RAMASASTRY, who serves as the Director of the company, bought 5,000 shares for $80.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 4137291264 and an Enterprise Value of 4057271552. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.77 while its Price-to-Book (P/B) ratio in mrq is 14.07. Its current Enterprise Value per Revenue stands at 8.6 whereas that against EBITDA is -230.986.
Stock Price History:
The Beta on a monthly basis for MIRM is 0.49, which has changed by 0.9288603 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, MIRM has reached a high of $81.70, while it has fallen to a 52-week low of $36.88. The 50-Day Moving Average of the stock is 13.06%, while the 200-Day Moving Average is calculated to be 36.70%.
Shares Statistics:
Over the past 3-months, MIRM traded about 713.65K shares per day on average, while over the past 10 days, MIRM traded about 1105220 shares per day. A total of 51.31M shares are outstanding, with a floating share count of 42.49M. Insiders hold about 17.79% of the company’s shares, while institutions hold 96.39% stake in the company. Shares short for MIRM as of 1764288000 were 7464991 with a Short Ratio of 10.46, compared to 1761868800 on 7027185. Therefore, it implies a Short% of Shares Outstanding of 7464991 and a Short% of Float of 14.530000000000001.
Earnings Estimates
A comprehensive evaluation of Mirum Pharmaceuticals Inc (MIRM) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.07, with high estimates of $0.04 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.18 and -$0.61 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.19, with 6.0 analysts recommending between $0.78 and -$0.73.
Revenue Estimates
8 analysts predict $135.76M in revenue for. The current quarter. It ranges from a high estimate of $138.6M to a low estimate of $131.3M. As of. The current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $99.41MFor the next quarter, 8 analysts are estimating revenue of $141.33M. There is a high estimate of $147.2M for the next quarter, whereas the lowest estimate is $137.89M.
A total of 9 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $511M, while the lowest revenue estimate was $503.7M, resulting in an average revenue estimate of $507.88M. In the same quarter a year ago, actual revenue was $336.89MBased on 7 analysts’ estimates, the company’s revenue will be $595.96M in the next fiscal year. The high estimate is $632.7M and the low estimate is $574.1M.
